Related Experiment Video
Updated: Jul 20, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells
Amy M Lin1, Robert M Hershberg, Eric J Small
1Department of Medicine, University of California, San Francisco, San Francisco, CA 94115, USA.
Urologic Oncology
|September 12, 2006
Summary
Dendritic cell therapy, using prostatic acid phosphatase (APC8015), improves survival in metastatic prostate cancer. This approach enhances T-cell responses against tumors, addressing immune deficiencies in cancer patients.
Area of Science:
- Immunology
- Oncology
- Cancer Therapy
Background:
- Dendritic cells are crucial for anti-tumor immunity but are deficient in cancer patients.
- This deficiency impairs T-cell responses and tumor immunosurveillance.
- Loaded dendritic cell therapy aims to overcome these limitations.
Purpose of the Study:
- To review clinical trials of APC8015 (Provenge) in prostate cancer.
- To discuss the role of APC8015 in treating metastatic hormone-refractory prostate cancer.
- To explore the future potential of APC8015 in prostate cancer treatment.
Main Methods:
- Review of randomized phase III clinical trials involving APC8015.
- Analysis of survival data and immune response induction.
- Discussion of therapeutic strategies using dendritic cell vaccination.
Main Results:
- APC8015 demonstrated a survival benefit in a phase III trial for metastatic hormone-refractory prostate cancer.
- The therapy elicits tumor antigen-specific T-cell immune responses.
- Dendritic cell therapy shows promise in enhancing anti-tumor immunity.
Conclusions:
- APC8015 is a viable therapeutic option for prostate cancer, offering survival advantages.
- Dendritic cell therapy represents a significant advancement in cancer immunotherapy.
- Further research into APC8015 may expand its role in prostate cancer management.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...